AdoShell Islets regulated glycemic control in immunocompetent diabetic animals in a 132-day trial without the use of insulin or immunosuppression. These results will be presented at the upcoming
Reinforced cash position of €23.9m at the end of June 2022 due to a $5m milestone payment from our partner Tonghua Dongbao (THDB) received in May 2022 Increase of first half revenues with
Adocia Announces Half Year Report on Adocia's Liquidity Agreement with Kepler Capital Markets finanznachrichten.de - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from finanznachrichten.de Daily Mail and Mail on Sunday newspapers.
Regulatory News: Adocia (Euronext Paris: FR0011184241 ADOC) (Paris:ADOC), a clinical-stage biopharmaceutical company focused on the research and development of innovative therapeutic solutions for
Demonstrated weight loss vs. Humalog (-2.13kg) over 4 months with progressive and continuous weight loss still ongoing at the end of study period. Both treatments were well tolerated and overall